Holen Sie sich die Stockscreener-App
108.10
0.23%
0.25
Schlusskurs vom Vortag:
$107.85
Offen:
$107.06
24-Stunden-Volumen:
638.47K
Relative Volume:
0.62
Marktkapitalisierung:
$6.05B
Einnahmen:
$1.34M
Nettoeinkommen (Verlust:
$-173.66M
KGV:
-26.12
EPS:
-4.1385
Netto-Cashflow:
$-130.49M
1W Leistung:
+2.14%
1M Leistung:
-2.08%
6M Leistung:
+74.27%
1J Leistung:
+338.36%
1-Tages-Spanne:
$105.65
$109.61
1-Wochen-Bereich:
$102.38
$110.44
52-Wochen-Spanne:
$24.48
$117.88
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Firmenname
Dianthus Therapeutics Inc
Sektor
Branche
Telefon
929-999-4055
Adresse
7 TIMES SQUARE, NEW YORK
Compare DNTH vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
108.10 | 6.13B | 1.34M | -173.66M | -130.49M | -4.1385 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-09 | Eingeleitet | Wolfe Research | Outperform |
| 2026-03-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2025-10-14 | Eingeleitet | Truist | Buy |
| 2025-07-02 | Eingeleitet | William Blair | Outperform |
| 2024-12-20 | Eingeleitet | TD Cowen | Buy |
| 2024-10-03 | Eingeleitet | Oppenheimer | Outperform |
| 2024-07-26 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-06-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-05-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-02-15 | Eingeleitet | Stifel | Buy |
| 2023-12-26 | Eingeleitet | Jefferies | Buy |
| 2023-11-22 | Eingeleitet | Wedbush | Outperform |
| 2023-10-30 | Eingeleitet | Guggenheim | Buy |
| 2023-09-28 | Eingeleitet | Raymond James | Outperform |
| 2022-08-25 | Herabstufung | Goldman | Buy → Neutral |
| 2022-01-06 | Hochstufung | Goldman | Neutral → Buy |
| 2021-08-20 | Fortgesetzt | Goldman | Neutral |
| 2021-08-03 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-22 | Bestätigt | B. Riley Securities | Buy |
| 2021-06-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-05-18 | Eingeleitet | B. Riley Securities | Buy |
| 2021-01-07 | Eingeleitet | Mizuho | Buy |
| 2020-06-08 | Hochstufung | Goldman | Neutral → Buy |
| 2019-03-25 | Herabstufung | Goldman | Buy → Neutral |
| 2019-03-15 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Dianthus Therapeutics Inc Aktie (DNTH) Neueste Nachrichten
Bank of America Corp DE Trims Stake in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Royal Bank of Canada Has $1.60 Million Stock Holdings in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Eagle Health Investments LP Takes Position in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Sets New 52-Week HighStill a Buy? - MarketBeat
Simon Read Sells 2,778 Shares of Dianthus Therapeutics (NASDAQ:DNTH) Stock - MarketBeat
Dianthus Therapeutics director Simon Read sells $326,553 in stock By Investing.com - Investing.com Australia
Dianthus Therapeutics director Simon Read sells $326,553 in stock - Investing.com
Dianthus (DNTH) Stock: Ends Down by 2.20% at $113.00 at the Close; Market Levels: the Supplied Trading Band Runs From $107.35 to $118.65 at the ClosePre-Earnings Momentum - Vinanet
Handelsbanken Fonder AB Invests $1.49 Million in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
DNTH Stock Clocks Best Day In Over 3 Months On Strong Nerve Disorder Study Results - Stocktwits
TimesSquare Capital Management LLC Acquires Shares of 166,357 Dianthus Therapeutics, Inc. $DNTH - MarketBeat
SCS Capital Management LLC Takes Position in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Walleye Capital LLC Takes Position in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics SVP Adam M. Veness Exercises 15,000 Stock Options at $18.17 Each - Kalkine Media
Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 52-Week HighTime to Buy? - MarketBeat
Dianthus Therapeutics stock hits 52-week high at 114.64 USD By Investing.com - Investing.com Nigeria
Dianthus Therapeutics stock hits 52-week high at 114.64 USD - Investing.com
Sirenia Capital reveals 1.70M-share DNTH stake in Dianthus Therapeutics (DNTH) - Stock Titan
Dianthus Therapeutics (DNTH): Wellington group discloses 3.23M-share, 5.9% passive stake - Stock Titan
Dianthus therapeutics director Simon Read sells $304k in stock By Investing.com - Investing.com South Africa
Dianthus Therapeutics SVP Adam Veness sells $2.2m common stock By Investing.com - Investing.com Nigeria
Dianthus therapeutics director Simon Read sells $304k in stock - Investing.com
Dianthus Therapeutics SVP Adam Veness sells $2.2m common stock - Investing.com
Anne Mcgeorge Sells 7,750 Shares of Dianthus Therapeutics (NASDAQ:DNTH) Stock - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) SVP Sells 16,167 Shares of Stock - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) SVP Sells $424,313.10 in Stock - MarketBeat
Dianthus Therapeutics Insider Sold Shares Worth $844,822, According to a Recent SEC Filing - marketscreener.com
DNTH insider Adam M. Veness plans Rule 144 sale of 16,167 shares - Stock Titan
Dianthus Therapeutics, Inc. /DE/ SEC Filing (Aug 10, 2026) - Stock Titan
Assenagon Asset Management S.A. Makes New Investment in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Evercore Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Raises Target Price to $134 - Moomoo
HC Wainwright Issues Optimistic Outlook for DNTH Earnings - MarketBeat
California State Teachers Retirement System Raises Stock Holdings in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics CEO Marino Garcia sells $17.9m in shares By Investing.com - Investing.com Australia
Dianthus Therapeutics CEO Marino Garcia sells $17.9m in shares - Investing.com
Dianthus Therapeutics(DNTH.US) Officer Sells US$17.95 Million in Common Stock - Moomoo
Marino Garcia Sells 166,000 Shares of Dianthus Therapeutics (NASDAQ:DNTH) Stock - MarketBeat
Dianthus Therapeutics, Inc. /DE/ SEC Filing (Aug 7, 2026) - stocktitan.net
Dynathera (DNTH) insider schedules 3,833-share stock sale under Rule 144 - Stock Titan
Dnth Holdings (DNTH) plans Rule 144 resale of 126,000 shares via Morgan Stanley - Stock Titan
Dianthus Therapeutics (DNTH): T. Rowe Price reports 12.1% ownership stake - Stock Titan
Dianthus Therapeutics (DNTH): T. Rowe Price reports 7.1% stake in common stock - Stock Titan
Dianthus Therapeutics CEO Marino Garcia reports disposal of 166,000 common shares worth $17.97 million - Bitget
Dianthus Therapeutics (DNTH) Stock Analysis: A Promising Biotech with 19.46% Potential Upside - DirectorsTalk Interviews
The Manufacturers Life Insurance Company Grows Holdings in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
DIANTHUS THERAPEUTICS INC : RAYMOND JAMES RAISES TARGET PRICE TO $131 FROM $125 - webull.com
DIANTHUS THERAPEUTICS INC : WEDBUSH RAISES TARGET PRICE TO $122 FROM $105 - webull.com
Finanzdaten der Dianthus Therapeutics Inc-Aktie (DNTH)
Umsatz
Nettogewinn
Free Cashflow
ENV
Dianthus Therapeutics Inc-Aktie (DNTH) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Read Simon | Director |
Aug 19 '26 |
Sale |
117.55 |
2,778 |
326,554 |
0 |
| Veness Adam M | SVP, General Counsel and Sec. |
Aug 13 '26 |
Option Exercise |
18.17 |
15,000 |
272,550 |
15,000 |
| McGeorge Anne | Director |
Aug 10 '26 |
Option Exercise |
12.52 |
7,750 |
97,000 |
7,750 |
| McGeorge Anne | Director |
Aug 10 '26 |
Sale |
109.01 |
7,750 |
844,822 |
0 |
| Read Simon | Director |
Aug 10 '26 |
Option Exercise |
18.36 |
2,777 |
50,986 |
2,777 |
| Read Simon | Director |
Aug 10 '26 |
Sale |
109.55 |
2,777 |
304,232 |
0 |
| Veness Adam M | SVP, General Counsel and Sec. |
Aug 10 '26 |
Option Exercise |
17.88 |
16,167 |
289,066 |
16,167 |
| Veness Adam M | SVP, General Counsel and Sec. |
Aug 07 '26 |
Option Exercise |
17.88 |
3,833 |
68,534 |
3,833 |
| Veness Adam M | SVP, General Counsel and Sec. |
Aug 10 '26 |
Sale |
110.38 |
16,167 |
1,784,513 |
0 |
| Veness Adam M | SVP, General Counsel and Sec. |
Aug 07 '26 |
Sale |
110.70 |
3,833 |
424,319 |
0 |
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):